Voxilaprevir

伏西瑞韦

Report date: 2023/10/24 20:10:17
NME

Base Information

Drug NameVoxilaprevir
Drug Alias NameGS-9857
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus serine protease, NS3/NS4A inhibitors
TargetsHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsHepatitis C, ChronicHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoNew Zealand +[4] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGilead Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGilead Sciences Inc
Active IndicationsN/A
Inactive IndicationsHepatitis C, ChronicHepatitis C

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG